US-based NKT Therapeutics has raised $4m in its second investment round from three investors, including Anglo-Swedish drugs company AstraZeneca’s corporate venturing division MedImmune Ventures. MedImmune declined to comment until the start of next year.
MedImmune and venture capital firm SV Life Sciences are on NKT’s website as investors and invested in the company’s $8m series A round in 2008, according to news provider Mass High Tech, which revealed the series B close.
NKT is developing drugs from the T cell (pictured).